Eli Lilly’s Obesity Drug Now Available in U.S. Pharmacies By Reuters
© Reuters. FILE PHOTO: Eli Lilly and Company pharmaceutical manufacturing plant is pictured March 5, 2021, at 50 ImClone Drive in Branchburg, NJ. REUTERS/Mike Segar/File Photo
(Reuters) – Eli Lilly’s (NYSE:) recently approved obesity treatment Zepbound is now available in U.S. pharmacies and customers with select insurance for $550 per month, or half the regular price, the U.S. drugmaker said on Tuesday.
The company is making weight loss medications accessible to adults through a commercial savings card program. The program allows people with commercial insurance to pay as little as $25 for a one- or three-month prescription.
On the other hand, adults with commercial insurance without coverage may be eligible to pay as little as $550 for a one-month prescription.
The drug was approved in November, paving the way for a powerful new competitor to Novo Nordisk’s (NYSE:) Wegovy in tackling record obesity rates.
Lilly’s drug, tirzepatide, has been available as Mounjaro for type 2 diabetes since 2022 and is increasingly being used ‘off-label’ for weight loss while its obesity approval is pending.
